A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 15, 2025

Primary Completion Date

July 31, 2029

Study Completion Date

July 31, 2034

Conditions

Locally Advanced Pancreatic AdenocarcinomaLocally Advanced Pancreas CancerLocally Advanced Pancreatic Ductal Adenocarcinoma

Interventions

DRUG

XER-001

XER-001 (Amifostine for nasoduodenal delivery)

All Listed Sponsors

lead

Xerient Pharma

INDUSTRY